
Biogen Inc.
BIIBHealthcare|Drug Manufacturers - General|US
$248.35
+4.42 (+1.81%)
DCF Value
$517.66
Graham Number
$82.35
Cash / Share
$8.82
Financials
Financial Snapshot
Market Cap
$36.71B
Enterprise Value
$43.21B
Revenue (TTM)
$10.30B
Net Income (TTM)
$348.0M
Cash & Investments
$1.30B
Net Cash
-$6.50B
Free Cash Flow (TTM)
$2.34B
Operating CF (TTM)
$2.25B
Debt/Equity
0.41
Cash Runway & Burn Rate
Company is cash-flow positive.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $4.90B | $3.69B | $3.54B | $4.48B | $2.61B | $3.80B | $4.89B | $1.05B | $2.38B | $3.82B | $1.30B | |
| Operating Cash Flow | $4.52B | $4.55B | $6.19B | $7.08B | $4.23B | $3.64B | $1.38B | $1.55B | $2.88B | $2.20B | $2.25B | |
| Free Cash Flow | $3.86B | $3.68B | $5.30B | $6.56B | $3.81B | $3.38B | $1.14B | $1.24B | $2.52B | $2.05B | $2.34B | |
| Capital Expenditure | -$616.1M | -$867.4M | -$770.6M | -$514.5M | -$424.8M | -$258.1M | -$240.3M | -$311.4M | -$359.8M | -$153.8M | $95.6M | |
| Financing Cash Flow | -$987.8M | -$2.38B | -$4.47B | -$5.86B | -$5.27B | -$2.09B | -$1.76B | $137.0M | -$683.5M | -$301.9M | $776.6M |
R&D Spending
R&D (TTM)
$2.15B
R&D Intensity
20.9%
R&D Growth vs Prior
+10.1%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.45B | $12.27B | $13.45B | $14.38B | $13.44B | $10.98B | $10.17B | $9.84B | $9.68B | $9.81B | $10.30B | |
| R&D Expense | $1.97B | $2.37B | $2.71B | $2.77B | $4.53B | $3.40B | $2.60B | $2.70B | $2.49B | $1.95B | $2.15B | |
| R&D % of Revenue | 17.2% | 19.3% | 20.1% | 19.3% | 33.7% | 31.0% | 25.5% | 27.5% | 25.7% | 19.9% | 20.9% | |
| SG&A | $1.95B | $1.94B | $2.11B | $2.36B | $2.52B | $2.68B | $2.41B | $2.50B | $2.39B | $2.43B | $2.75B |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.45B | $12.27B | $13.45B | $14.38B | $13.44B | $10.98B | $10.17B | $9.84B | $9.68B | $9.81B | $10.30B | |
| Cost of Revenue | $1.43B | $1.63B | $1.82B | $1.96B | $1.81B | $2.11B | $2.28B | $2.53B | $2.31B | $2.90B | $3.08B | |
| Gross Profit | $10.02B | $10.64B | $11.64B | $12.42B | $11.64B | $8.87B | $7.90B | $7.30B | $7.37B | $6.91B | $7.21B | |
| R&D | $1.97B | $2.37B | $2.71B | $2.77B | $4.53B | $3.40B | $2.60B | $2.70B | $2.49B | $1.95B | $2.15B | |
| SG&A | $1.95B | $1.94B | $2.11B | $2.36B | $2.52B | $2.68B | $2.41B | $2.50B | $2.39B | $2.43B | $2.75B | |
| Operating Income | $5.15B | $5.35B | $5.89B | $7.04B | $4.59B | $2.79B | $2.89B | $2.10B | $2.49B | $1.88B | $786.9M | |
| Interest Expense | $260.0M | $250.8M | $200.6M | $187.4M | $222.5M | $253.6M | $246.6M | $246.9M | $250.3M | $246.0M | $304.9M | |
| Pretax Income | $4.93B | $5.13B | $5.90B | $7.05B | $5.05B | $1.78B | $3.59B | $1.30B | $1.91B | $1.40B | $290.1M | |
| Net Income | $3.70B | $2.54B | $4.43B | $5.89B | $4.00B | $1.56B | $3.05B | $1.16B | $1.63B | $1.29B | $348.0M | |
| EPS (Diluted) | 16.93 | 11.92 | 21.58 | 31.42 | 24.80 | 10.40 | 20.87 | 7.97 | 11.19 | 8.83 | 2.34 | |
| EBITDA | $6.39B | $6.61B | $7.01B | $7.74B | $5.11B | $3.92B | $3.54B | $2.38B | $3.00B | $2.95B | $1.45B | |
| Shares Out. (M) | 218.80 | 213.00 | 205.30 | 187.40 | 161.30 | 149.60 | 146.00 | 145.60 | 145.90 | 146.70 | 147.80 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.33B | $1.57B | $1.22B | $2.91B | $1.33B | $2.26B | $3.42B | $1.05B | $2.38B | $3.01B | $1.30B | |
| Short-Term Investments | $2.57B | $2.12B | $2.31B | $1.56B | $1.28B | $1.54B | $1.47B | $0.00 | $0.00 | $807.2M | $0.00 | |
| Total Current Assets | $8.73B | $7.87B | $7.64B | $8.38B | $6.89B | $7.86B | $9.79B | $6.86B | $7.46B | $8.97B | $7.58B | |
| Total Assets | $22.88B | $23.65B | $25.29B | $27.23B | $24.62B | $23.88B | $24.55B | $26.84B | $28.05B | $29.44B | $32.05B | |
| Total Current Liabilities | $3.42B | $3.37B | $3.30B | $4.86B | $3.74B | $4.30B | $3.27B | $3.43B | $5.53B | $3.35B | $3.90B | |
| Long-Term Debt | $6.51B | $5.93B | $5.94B | $4.46B | $7.43B | $6.27B | $6.28B | $6.79B | $4.55B | $6.58B | $7.29B | |
| Total Liabilities | $10.75B | $11.05B | $12.26B | $13.90B | $13.93B | $12.92B | $11.17B | $12.05B | $11.33B | $11.18B | $13.13B | |
| Stockholders' Equity | $12.14B | $12.61B | $13.04B | $13.34B | $10.70B | $10.90B | $13.40B | $14.80B | $16.72B | $18.26B | $18.92B | |
| Retained Earnings | $15.07B | $15.81B | $16.26B | $16.46B | $13.98B | $13.91B | $16.47B | $17.63B | $19.26B | $20.55B | $20.95B |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $4.52B | $4.55B | $6.19B | $7.08B | $4.23B | $3.64B | $1.38B | $1.55B | $2.88B | $2.20B | $2.25B | |
| Capital Expenditure | -$616.1M | -$867.4M | -$770.6M | -$514.5M | -$424.8M | -$258.1M | -$240.3M | -$311.4M | -$359.8M | -$153.8M | $95.6M | |
| Free Cash Flow | $3.86B | $3.68B | $5.30B | $6.56B | $3.81B | $3.38B | $1.14B | $1.24B | $2.52B | $2.05B | $2.34B | |
| Investing Cash Flow | -$2.48B | -$2.96B | -$2.05B | $470.5M | -$608.6M | -$563.7M | $1.59B | -$4.09B | -$799.2M | -$1.37B | -$5.50B | |
| Financing Cash Flow | -$987.8M | -$2.38B | -$4.47B | -$5.86B | -$5.27B | -$2.09B | -$1.76B | $137.0M | -$683.5M | -$301.9M | $776.6M | |
| Issuance of Stock | $43.7M | -$5.3M | -$2.1M | $0.00 | -$4.6M | -$700.0K | -$1.9M | -$44.3M | -$31.3M | -$10.0M | $6.2M | |
| Repurchase of Stock | -$1.00B | -$1.37B | -$4.35B | -$5.87B | -$6.68B | -$1.80B | -$750.0M | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | -$2.7M | -$560.9M | -$3.2M | $0.00 | $1.47B | -$170.0M | -$1.00B | $187.3M | -$650.0M | -$16.9M | -$400.0M | |
| Stock Based Comp. | $154.8M | $128.0M | $157.5M | $182.3M | $198.3M | $238.6M | $254.1M | $264.2M | $291.2M | $290.8M | $141.1M | |
| Net Change in Cash | $1.02B | -$752.7M | -$349.2M | $1.69B | -$1.58B | $930.2M | $1.16B | -$2.37B | $1.33B | $633.5M | -$2.51B |
Dilution Tracker
Shares Outstanding
148M
5-Year Share Growth
-9.1%
Stock Issuance (TTM)
$6.2M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 218.80 | 213.00 | 205.30 | 187.40 | 161.30 | 149.60 | 146.00 | 145.60 | 145.90 | 146.70 | 147.80 | |
| Change vs Prior % | — | -2.7% | -3.6% | -8.7% | -13.9% | -7.3% | -2.4% | -0.3% | 0.2% | 0.5% | 0.7% | |
| Stock Issuance | $43.7M | -$5.3M | -$2.1M | $0.00 | -$4.6M | -$700.0K | -$1.9M | -$44.3M | -$31.3M | -$10.0M | $6.2M | |
| Stock Repurchase | -$1.00B | -$1.37B | -$4.35B | -$5.87B | -$6.68B | -$1.80B | -$750.0M | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $154.8M | $128.0M | $157.5M | $182.3M | $198.3M | $238.6M | $254.1M | $264.2M | $291.2M | $290.8M | $141.1M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 87.5% | 86.7% | 86.5% | 86.4% | 86.6% | 80.8% | 77.6% | 74.2% | 76.1% | 70.5% | 70.0% | |
| Operating Margin % | 45.0% | 43.6% | 43.8% | 49.0% | 34.2% | 25.4% | 28.4% | 21.3% | 25.7% | 19.1% | 7.6% | |
| Net Margin % | 32.3% | 20.7% | 32.9% | 41.0% | 29.8% | 14.2% | 29.9% | 11.8% | 16.9% | 13.2% | 3.4% | |
| EBITDA Margin % | 55.8% | 53.8% | 52.1% | 53.8% | 38.0% | 35.7% | 34.8% | 24.2% | 31.0% | 30.0% | 14.1% | |
| FCF Margin % | 33.7% | 30.0% | 39.4% | 45.7% | 28.3% | 30.8% | 11.2% | 12.6% | 26.0% | 20.9% | 22.8% | |
| ROE % | 30.5% | 20.1% | 34.0% | 44.1% | 37.4% | 14.3% | 22.7% | 7.8% | 9.8% | 7.1% | 1.9% | |
| ROA % | 16.2% | 10.7% | 17.5% | 21.6% | 16.3% | 6.5% | 12.4% | 4.3% | 5.8% | 4.4% | 1.1% | |
| ROIC % | 19.8% | 13.7% | 20.3% | 24.7% | 17.7% | 13.2% | 11.2% | 8.0% | 8.8% | 6.6% | 2.8% | |
| R&D / Revenue % | 17.2% | 19.3% | 20.1% | 19.3% | 33.7% | 31.0% | 25.5% | 27.5% | 25.7% | 19.9% | 20.9% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.4% | 7.2% | 9.6% | 6.9% | -6.5% | -18.3% | -7.4% | -3.3% | -1.6% | 1.4% | |
| Gross Profit | 5.2% | 6.3% | 9.3% | 6.8% | -6.3% | -23.8% | -11.0% | -7.5% | 0.9% | -6.1% | |
| Operating Income | 5.3% | 3.8% | 10.2% | 19.6% | -34.8% | -39.2% | 3.5% | -27.4% | 18.7% | -24.6% | |
| Net Income | 4.4% | -31.4% | 74.5% | 32.9% | -32.1% | -61.1% | 95.8% | -61.9% | 40.6% | -20.8% | |
| EPS (Diluted) | 10.4% | -29.6% | 81.0% | 45.6% | -21.1% | -58.1% | 100.7% | -61.8% | 40.4% | -21.1% | |
| Operating Cash Flow | 21.7% | 0.6% | 36.0% | 14.4% | -40.2% | -13.9% | -62.0% | 11.8% | 85.9% | -23.3% | |
| Free Cash Flow | 25.6% | -4.6% | 43.9% | 23.8% | -42.0% | -11.1% | -66.2% | 8.0% | 103.6% | -18.5% | |
| R&D Expense | -2.0% | 20.3% | 14.2% | 2.2% | 63.5% | -24.9% | -23.6% | 4.1% | -7.9% | -21.5% | |
| SG&A Expense | -7.7% | -0.7% | 8.9% | 11.8% | 6.6% | 6.5% | -10.1% | 3.9% | -4.6% | 2.0% | |
| Total Assets | 17.3% | 3.4% | 6.9% | 7.7% | -9.6% | -3.0% | 2.8% | 9.3% | 4.5% | 5.0% | |
| Book Value / Share | 36.7% | 6.7% | 7.3% | 12.1% | -6.8% | 10.7% | 25.4% | 11.0% | 12.2% | 8.5% | |
| Debt | -0.1% | -8.9% | -0.0% | 7.3% | 22.9% | -2.9% | -13.0% | 10.9% | -9.6% | 4.8% | |
| Diluted Shares | -5.4% | -2.7% | -3.6% | -8.7% | -13.9% | -7.3% | -2.4% | -0.3% | 0.2% | 0.5% |
Valuation
P/E (TTM)105.23
10Y Low / Med / High9.43 / 16.72 / 32.27
P/S3.57
10Y Low / Med / High2.30 / 3.86 / 5.52
P/B1.94
10Y Low / Med / High1.33 / 3.68 / 5.37
EV/EBITDA29.83
10Y Low / Med / High7.62 / 10.35 / 18.40
EV/Revenue4.20
10Y Low / Med / High2.74 / 4.27 / 5.87
P/FCF15.67
10Y Low / Med / High8.46 / 12.59 / 35.17
Intrinsic Value Models (per share)
DCF Value
$517.66
Graham Number
$82.35
Cash / Share
$8.82
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | 16.72 | 26.68 | 13.92 | 9.43 | 9.85 | 22.98 | 13.21 | 32.27 | 13.65 | 19.89 | 105.23 | |
| P/S Ratio | 5.41 | 5.52 | 4.58 | 3.86 | 2.93 | 3.26 | 3.96 | 3.81 | 2.30 | 2.63 | 3.57 | |
| P/B Ratio | 5.10 | 5.37 | 4.73 | 4.16 | 3.68 | 3.28 | 3.00 | 2.53 | 1.33 | 1.41 | 1.94 | |
| EV/EBITDA | 10.35 | 10.91 | 9.46 | 7.62 | 8.98 | 10.48 | 12.28 | 18.40 | 8.86 | 10.10 | 29.83 | |
| EV/Revenue | 5.78 | 5.87 | 4.93 | 4.10 | 3.41 | 3.74 | 4.27 | 4.45 | 2.74 | 3.03 | 4.20 |
Analyst Estimates & Quality
Altman Z-Score
3.11
Safe
Piotroski F-Score
5
Moderate
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $10.58B | $10.78B | $11.13B |
| Net Income | $1.86B | $2.41B | $2.71B |
| EPS | $12.49 | $16.22 | $18.34 |
| # Analysts (EPS) | 19 | 21 | 11 |
Revenue Segments
By Product
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Fumarate | $3.91B | $2.36B | $2.00B | $1.59B | $1.60B | $1.43B |
| Interferon | $1.88B | $1.57B | $1.31B | $1.11B | $968.0M | $945.6M |
| MS Product Revenues | $7.83B | $6.10B | $5.43B | $4.66B | $4.35B | $4.04B |
| SPINRAZA | $2.05B | $1.91B | $1.79B | $1.74B | $1.57B | $1.55B |
| TYSABRI product | $1.95B | $2.06B | $2.03B | $1.88B | $1.72B | $1.67B |
By Geography
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Non-US | $4.79B | $5.04B | $4.52B | — | $3.98B | $3.57B |
| UNITED STATES | $5.90B | $3.81B | $3.47B | $3.14B | $3.24B | $2.37B |
| Asia | — | — | — | $649.4M | — | — |
| Europe | — | — | — | $2.13B | — | — |
| GERMANY | — | — | — | $868.0M | — | — |